OncoMatch/Clinical Trials/NCT06797999
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Is NCT06797999 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Antibody-drug conjugate (ADC) for metastatic soft tissue sarcoma.
Treatment: Antibody-drug conjugate (ADC) — The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cytotoxic chemotherapy — metastatic/unresectable
Prior treatment with at least one but no more than two lines of cytotoxic systemic therapy for metastatic/unresectable disease
Cannot have received: systemic anticancer therapy
Patients who have had systemic anticancer therapy, including any investigational agent within 4 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Denver · Aurora, Colorado
- University of Miami - Sylvester Comprehensive Cancer Center · Miami, Florida
- Memorial Sloan Kettering Cancer Center · New York, New York
- University Of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06797999 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages